Anke Biotech announced that recently, its wholly-owned subsidiary Shanghai Soho Yiming Pharmaceutical Co., Ltd. received the CEP certificate for octreotide APIs issued by the European Medicines Quality Administration, which will take effect from July 31, 2026. This is the 3rd CEP certification for polypeptide APIs obtained by Soho Yiming. It will obtain entry qualifications for the company's octreotide APIs into the EU market, which will help expand overseas markets for peptide APIs. However, product sales are affected by factors such as the market environment, and there is uncertainty.

Anke Biotech announced that recently, its wholly-owned subsidiary Shanghai Soho Yiming Pharmaceutical Co., Ltd. received the CEP certificate for octreotide APIs issued by the European Medicines Quality Administration, which will take effect from July 31, 2026. This is the 3rd CEP certification for polypeptide APIs obtained by Soho Yiming. It will obtain entry qualifications for the company's octreotide APIs into the EU market, which will help expand overseas markets for peptide APIs. However, product sales are affected by factors such as the market environment, and there is uncertainty.